Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
about
A phase one, single-dose, open-label, clinical safety and PET/MR imaging study of 68Ga-DOTATOC in healthy volunteers.Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinomaPeptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity86Y based PET radiopharmaceuticals: radiochemistry and biological applicationsInfluence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy.Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy.Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology.Measured human dosimetry of 68Ga-DOTATATE.Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors.Time to demand dosimetry for molecular radiotherapy?Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumoursThe joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursPreclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimatesMethod dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy.Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.Imaging in targeted delivery of therapy to cancer.Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review.The molecular pathogenesis and management of bronchial carcinoids.Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?Yttrium-labelled peptides for therapy of NET.Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT.Radiolabeled peptides: valuable tools for the detection and treatment of cancerImpact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers.Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours.Dimeric DOTA-alpha-melanocyte-stimulating hormone analogs: synthesis and in vivo characteristics of radiopeptides with high in vitro activity.Long-term results of PRRT in advanced bronchopulmonary carcinoid.Neuroendocrine tumors: a focus on liver metastatic lesions.Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors.Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate.Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues.The role of multimodal treatment in patients with advanced lung neuroendocrine tumors.Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT.Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.Cervical metastases of glucagonoma in a patient with multiple endocrine neoplasia type 1: report of a case.Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease.
P2860
Q33700120-5494EC11-47EF-42CA-94AC-C2EB24094919Q34987688-EAAB4C09-328C-4446-AE4A-ACDF08A9EA65Q35176280-E81A6DED-B9E0-4EC9-8CAB-C2AD37AD1B0AQ35250409-5D9BBC77-B45E-408D-A6E6-718792331641Q35545959-E6F8D2C7-200E-4961-968E-E418038BF4CBQ35545967-D03E33BD-21B1-4481-AC14-743640F1710AQ35602256-7392CA8D-505D-4422-A9C3-F9B5D1766DDAQ35756123-E46CC008-EBB6-40E4-866A-A17E4AE78506Q35880923-A274407F-FE96-401C-A32C-9B7EB066C5F1Q36008285-76BD966E-4C08-4A28-BAD1-528B7A3CF9AAQ36295237-D65F7189-1A13-4B13-9676-F634B2E9BBA9Q36300599-D5496ABE-CE94-4640-BDC8-69705B1ADD08Q36510103-1B5F6490-2224-4FFA-A82E-681544F5F1ABQ36755905-2327EE94-2EF2-48C9-9AFE-DC9D37945C69Q36928870-91005FFD-6F8A-4D3D-8790-65FC06E79505Q36942728-7482E4AF-E213-44DB-AABE-F70660FABCC0Q37167160-28DE9F1F-DFE0-45DB-90CF-9D12A4E6C1ABQ37201458-2A63B06E-704A-43A8-A3B7-115D71DECAF2Q37617137-A3D46E8E-21CE-42B8-888A-31875EE7B510Q37812297-CD2D6C5F-4ACB-4C52-898C-F2D38F87B5A9Q37833109-4F5791B6-39C8-4B65-8A1D-5740DE7721E7Q37864161-C07FC931-058E-443B-A0C7-2D473090B53AQ37990401-98064174-0668-4210-8C59-F975F7ED5194Q38884776-7825CC66-C990-46C4-B738-58A7F693B1CFQ38909078-C84CEA8F-D4F5-4DAC-9A48-CCD550CF2F60Q39519197-E69908C9-4CDE-4F13-B72C-1AA397808F9FQ39596344-73D0F2CD-C38B-4320-81E5-14C3A2FFF25BQ39755513-C03FE8A3-8E08-430E-9BB9-4208BC49CE61Q39827654-54B8CEFF-8038-48E7-9597-45727E4FB95BQ40031973-61DA4B91-0684-4101-AC18-41AF0EF4559DQ40516842-E1DA11BF-A55C-4BF2-9619-FC16B6113989Q42175071-EAF42F66-62D3-4483-9D76-50597E8F2705Q42548064-75666633-BA9E-4157-84DC-8120C8C8362CQ43281607-D5ACDE04-7BE9-4B88-BCFF-DE45138296EEQ44384822-390C78C1-25DB-42DC-9DCD-E3EFB388483FQ45896572-A8425B4C-8456-4926-9E17-9E187A5C9494Q46022237-193BAD53-61C8-4CA2-97EB-7C076023A183Q46075799-59D3B03A-B9E0-486E-828B-4CC2028B09B2Q46224682-CEF691FA-260A-41F5-AF3C-DD8057B5E202Q46599160-680370EC-8A36-4931-8D70-3BD99D087153
P2860
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Receptor radionuclide therapy ...... OC) in neuroendocrine tumours.
@ast
Receptor radionuclide therapy ...... OC) in neuroendocrine tumours.
@en
type
label
Receptor radionuclide therapy ...... OC) in neuroendocrine tumours.
@ast
Receptor radionuclide therapy ...... OC) in neuroendocrine tumours.
@en
prefLabel
Receptor radionuclide therapy ...... OC) in neuroendocrine tumours.
@ast
Receptor radionuclide therapy ...... OC) in neuroendocrine tumours.
@en
P2093
P1476
Receptor radionuclide therapy ...... OC) in neuroendocrine tumours.
@en
P2093
Chiara Grana
Giovanni Paganelli
Lisa Bodei
Marco Chinol
Marta Cremonesi
Mirco Bartolomei
Paola Rocca
P2888
P304
P356
10.1007/S00259-004-1571-4
P577
2004-05-19T00:00:00Z